MedPage Today on MSN
Parkinson's disease gets new treatment approved
FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...
Los Angeles Rams tight end Colby Parkinson suffered an AC joint sprain in Week 3 ...
Head coach Sean McVay told reporters Monday that tight end Terrance Ferguson likely won't play against the Philadelphia ...
Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...
In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with ...
Dennis Haskins lived with Parkinson's disease for about eight years before his death at 75, keeping the diagnosis largely out ...
US Magazine on MSN
Saved By the Bell's Dennis Haskins Battled Parkinson's Before His Death
New details surrounding Dennis Haskins’ health have been revealed after his death at the age of 75. Haskins’ friend and ...
Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
Today's FDA approval of tavapadon makes it the first selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease.
Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results